FDA OK's HIF2α Inhibitor Belzutifan

In a first, the FDA has approved an inhibitor of hypoxia-inducible factor-2α. The drug is also the first approved to treat von Hippel-Lindau disease-associated renal cell carcinoma, central nervous system hemangioblastomas, and pancreatic neuroendocrine tumors.